Apogee’s zumilokibart continued to generate efficacy support as the biotech positioned for Phase 3. Reporting highlighted the company’s Part B 16-week APEX results, with outcomes used to bolster the case for a late-stage program aimed at capturing broader market share against dupilumab and other IL-13–centered regimens. The company’s Phase 3 timing remains conditioned on discussions with regulators, but the financing package from Blackstone is designed to absorb those near-term execution risks. Apogee also framed the drug as a potentially differentiated, long-acting anti-IL-13 option, with implications for dosing convenience and disease-control durability. For the competitive landscape, stronger induction and response durability signals can be decisive when payers and prescribing guidelines evaluate new biologics for first-line use in atopic dermatitis.